IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE

Applicants: Mark Quang Nguyen, San Jose, CA (US); Archana Gangakhedkar, San Jose, CA (US)

Inventors: Mark Quang Nguyen, San Jose, CA (US); Archana Gangakhedkar, San Jose, CA (US)

Appl. No.: 15/180,018
Filed: Jun. 11, 2016

Related U.S. Application Data
Division of application No. 14/738,907, filed on Jun. 14, 2015, now Pat. No. 9,394,312.

Publication Classification

Int. Cl. A61K 31/519 (2006.01)
A61K 9/00 (2006.01)

U.S. Cl. CPC A61K 31/519 (2013.01); A61K 9/0053 (2013.01)

ABSTRACT

Prodrugs of ibrutinib, pharmaceutical compositions comprising the prodrugs, and methods of using the prodrugs and pharmaceutical compositions for treating autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions are disclosed.
Disclosed herein are ibrutinib prodrugs, pharmaceutical compositions comprising ibrutinib prodrugs, and methods of using ibrutinib prodrugs and pharmaceutical compositions thereof for treating autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

BACKGROUND

Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is approved in the United States for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and lymphoplasmacytic lymphoma (U.S. Pat. Nos. 7,514,444, 7,718,662, 8,476,284, 8,497,277, 8,703,780, and 8,735,403). The recommended dose of ibrutinib is 420 to 560 mg orally once daily. However, the absolute bioavailability of ibrutinib in fasted humans (n=8) was 2.9% (90% CI=1.2-5.9) and doubled when combined with a meal (European Medicines Agency).

The need for higher ibrutinib dosage to counter its low oral bioavailability may be responsible for adverse side effects such as nausea or emesis, dizziness and diarrhea. Moreover, the low oral bioavailability may result in variable absorption and therapeutic response.

SUMMARY

Ibrutinib prodrugs having higher oral bioavailability than the parent compound may: reduce gastrointestinal side effects/toxicity such as nausea or emesis, dizziness and diarrhea; facilitate the use of lower doses; reduce food effects; reduce interpatient treatment variability; and enhance the efficacy/responder rate.

In a first aspect, compounds of Formula (I) are provided:

\[
\text{Formula (I)}
\]

or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein:

- A is selected from N and CR';
- X is selected from bond, O, —C(=O)—, S, —S(=O)—, —S(=O)2—, —NH—, —NR14—, —NHCH(O)O—, —NHCH(O)NH—, —OCH(O)NH—, and —OCH(O)O—;
- L' is a bond, O, S, —S(=O)—, —S(=O)2—, —NH—, —C(O)—, —CH2—, —NHCH(O)O—, —NHCH(O)NH—, or —C(O)NH—;
- L' is a bond, O, S, —S(=O)—, —S(=O)2—, —NH—, —C(O)—, —CH2—, —NHCH(O)O—, —NHCH(O)NH—, or —C(O)NH—;
- R' is selected from H and lower alkyl;
- R' is L2-X-L3-G', wherein,

- L2 is selected from a bond, substituted or unsubstituted alkyle, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenylene, and substituted or unsubstituted aralkylene;
- X is selected from a bond, O, —C(=O)—, —S(=O)—, —S(=O)2—, —NH—, —NR14—, —NHCH(O)O—, —NHCH(O)NH—, —OCH(O)NH—, —OCH(O)O—, —ON—CH—, —NR15—C(=O)NR15—, —NR15—C(=O)—, —CN—, —NO2—, heteroalkylene, and —C(=O)—;
- R11, R12, and R13 are selected from the following structures:

\[
\text{Structures (II)}
\]

or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein:

- A is selected from N and CR11;
- each R12, R16, R19, and R15 is independently selected from H, halogen, —CF3, —CN, —NO2, OMe, NH2, —L1—(substituted or unsubstituted alkyle), —L1—(substituted or unsubstituted heterocyclic ring); and

G is selected from the following structures:

\[
\text{Structures (III)}
\]
and

Z is selected from the following structures:

![Chemical structures]

wherein each \( R_{11}^{13} \), \( R_{12}^{13} \), and \( R_{13}^{13} \) is independently selected from \( \mathrm{H} \), substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl.

In a second aspect, pharmaceutical compositions are provided comprising a compound of Formula (I) and at least one pharmaceutically acceptable vehicle.

In a third aspect, methods of treating a disease in a patient are provided comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I). In certain embodiments, the disease is chosen from an autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

DETAILED DESCRIPTION

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and/or" unless stated otherwise. Furthermore, use of the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in the application including, but not limited to, patents, patent applications, articles, books, manuals, and treatises are hereby expressly incorporated by reference in their entirety for any purpose.

Definition of standard chemistry terms may be found in reference works, including Carey and Sundberg “ADVANCED ORGANIC CHEMISTRY 4TH ED.” Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art are employed. Unless specific definitions are provided, the nomenclature employed in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those known in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques can be performed e.g., using kits of manufacturer’s specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can be generally performed of conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification.

It is to be understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described herein, which will be limited only by the appended claims.

All publications and patents mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing for example, the constructs and methodologies that are described in the publications, which might be used in connection with the methods, compositions and compounds described herein. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors described herein are not entitled to antedate such disclosure by virtue of prior invention or for any other reason.

An “alkyl” group refers to an aliphatic hydrocarbon group. The alkyl moiety may be a “saturated alkyl” group, which means that it does not contain any alkene or alkyne moieties. The alkyl moiety may also be an “unsaturated alkyl” moiety, which means that it contains at least one alkene or alkyne moiety. An “alkene” moiety refers to a group that has at least one carbon-carbon double bond, and an “alkyne” moiety refers to a group that has at least one carbon-carbon triple bond. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic. Depending on the structure, an alkyl group can be a
monoradical or a diradical (i.e., an alkylene group). The alkyl group could also be a “lower alkyl” having 1 to 6 carbon atoms.

[0029] As used herein, C₁₋₄ includes C₁₋₂, C₁₋₃, . . . , C₁₋₄.

[0030] The “alkyl” moiety may have 1 to 10 carbon atoms (whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group of the compounds described herein may be designated as “C₁₋₄ alkyl” or similar designations. By way of example only, “C₁₋₄ alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from among methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Thus C₁₋₄ alkyl includes C₁₋₂ alkyl and C₁₋₃ alkyl. Alkyl groups can be substituted or unsubstituted. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0031] As used herein, the term “non-cyclic alkyl” refers to an alkyl that is not cyclic (i.e., a straight or branched chain containing at least one carbon atom). Non-cyclic alkyls can be fully saturated or can contain non-cyclic alkenes and/or alkenes. Non-cyclic alkyls can be optionally substituted.

[0032] The term “alkenyl” refers to a type of alkyl group in which the first two atoms of the alkyl group form a double bond that is not part of an aromatic group. That is, an alkene group begins with the atoms —R₁—C=—R₂—, wherein R₁ and R₂ refer to the remaining portions of the alkyl group, which may be the same or different. The alkene moiety may be branched, straight chain, or cyclic (in which case, it would also be known as a “cycloalkenyl” group). Depending on the structure, an alkene group can be a monoradical or a diradical (i.e., an alkylene group). Alkene groups can be optionally substituted. Non-limiting examples of an alkene group include —CH=—CH₂, —C(CH₃)=—CH₂, —CH=—CH(CH₃), —C(CH₃)=—CH(CH₃), —CH=—CH₂CH₂—, —C(CH₃)=—CH₂CH₂—, and —C(CH₃)=—CH₂CH₂—. Alkene groups can have 2 to 10 carbons. The alkene group could also be a “lower alkene” having 2 to 6 carbon atoms.

[0033] The term “alkynyl” refers to a type of alkyl group in which the first two atoms of the alkyl group form a triple bond. That is, an alkynyl group begins with the atoms —C—C=—R, wherein R refers to the remaining portions of the alkynyl group, which may be the same or different. The “R” portion of the alkynyl moiety may be branched, straight chain, or cyclic. Depending on the structure, an alkynyl group can be a monoradical or a diradical (i.e., an alkynylene group). Alkynyl groups can be optionally substituted. Non-limiting examples of an alkynyl group include, but are not limited to, —C=—CH, —C=—CH₂, —C=—C(CH₃), —C=—CH₂CH₂—, and —C=—C(CH₃)₂—. Alkynyl groups can have 2 to 10 carbons. The alkynyl group could also be a “lower alkynyl” having 2 to 6 carbon atoms.

[0034] An “alkoxy” group refers to a (alkyl)O— group, where alkyl is as defined herein.

[0035] “Hydroxyalkyl” refers to an alkyl radical, as defined herein, substituted with at least one hydroxy group. Non-limiting examples of a hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 2-hydroxyprop-1-yl, 2-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2-hydroxybut-1-yl, 2-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl.

[0036] “Alkoxyalkyl” refers to an alkyl radical, as defined herein, substituted with an alkoxy group, as defined herein.

[0037] An “alkenylxoy” group refers to a (alkenyl)O— group, where alkenyl is as defined herein.

[0038] The term “alkylamine” refers to the —N(alkyl)H₂, group, where x and y are selected from among x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, taken together with the N atom to which they are attached, can optionally form a cyclic ring system.

[0039] “Alkylaminooalkyl” refers to an alkyl radical, as defined herein, substituted with an alkylamine, as defined herein.

[0040] An “amide” is a chemical moiety with the formula —C(O)NH(R) or —NH(C(O)R), where R is selected from among alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroaromatic (bonded through a ring carbon). An amide moiety may form a linkage between an amino acid or a peptide molecule and a compound described herein, thereby forming a prodrug. Any amine, or carboxylate side chain on the compounds described herein can be amidified. The procedures and specific groups to make such amides are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein by reference in its entirety.

[0041] The term “ester” refers to a chemical moiety with formula —COOR, where R is selected from among alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroaromatic (bonded through a ring carbon). Any hydroxy, or carboxylate side chain on the compounds described herein can be esterified. The procedures and specific groups to make such esters are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, which is incorporated herein by reference in its entirety.

[0042] As used herein, the term “ring” refers to any covalently closed structure. Rings include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and non-aromatic heterocycles), aromatics (e.g., aryls and heteroaryls), and non-aromatics (e.g., cycloalkyls and non-aromatic heterocycles). Rings can be optionally substituted. Rings can be monocyclic or polycyclic.

[0043] As used herein, the term “ring system” refers to one, or more than one ring.

[0044] The term “membered ring” can embrace any cyclic structure. The term “membered” is meant to denote the number of skeletal atoms that constitute the ring. Thus, for example, cyclohexyl, pyridine, pyran and thiopyran are 6-membered rings and cyclopentyl, pyrrole, furan, and thiophene are 5-membered rings.

[0045] The term “fused” refers to structures in which two or more rings share one or more bonds.
The term “carbocyclic” or “carbocycle” refers to a ring wherein each of the atoms forming the ring is a carbon atom. Carbocycle includes aryl and cycloalkyl. The term thus distinguishes carbocycle from heterocycle (“heterocyclic”) in which the ring backbone contains at least one atom which is different from carbon (i.e., a heteroatom). Heterocycle includes heteroaryl and heterocycloalkyl. Carbocycles and heterocycles can be optionally substituted.

The term “aromatic” refers to a planar ring having a delocalized π-electron system containing 4n+2π electrons, where n is an integer. Aromatic rings can be formed from five, six, seven, eight, nine, or more than nine atoms. Aromatics can be optionally substituted. The term “aromatic” includes both carbocyclic aryl (e.g., phenyl) and heterocyclic aryl (or “heteroaryl” or “heteroaromatic”) groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.

As used herein, the term “aryl” refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl rings can be formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups can be optionally substituted. Examples of aryl groups include but are not limited to phenyl, naphthalenyl, phenanthrenyl, anthracenyl, fluorenyl, and indenyl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group).

An “aryloxy” group refers to an (aryl)O— group, where aryl is as defined herein.

“Aralkyl” means an alkyl radical, as defined herein, substituted with an aryl group. Non-limiting aralkyl groups include benzyl, phenethyl, and the like.

“Aralkenyl” means an alkenyl radical, as defined herein, substituted with an aryl group, as defined herein.

The term “cycloalkyl” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and may be saturated, partially unsaturated, or fully unsaturated. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Illustrative examples of cycloalkyl groups include the following moieties:

and the like. Depending on the structure, a cycloalkyl group can be a monoradical or a diradical (e.g., a cycloalkylene group). The cycloalkyl group could also be a “lower cycloalkyl” having 3 to 8 carbon atoms.

“Cycloalkylalkyl” means an alkyl radical, as defined herein, substituted with a cycloalkyl group. Non-limiting cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

The term “heterocycle” refers to heteroaromatic and heterocyclic groups containing one to four heteroatoms each selected from O, S, and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. A heteroatom is present in the ring. Designations such as “C1-C8 heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. It is understood that the heterocyclic ring can have additional heteroatoms in the ring. Designations such as “4-6 membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). In heterocycles that have two or more heteroatoms, those two or more heteroatoms can be the same or different from one another. Heterocycles can be optionally substituted. Binding to a heterocycle can be at a heteroatom or via a carbon atom. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 4-membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5-membered heterocyclic group is thiazolyl. An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10-membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuran, dihydropyran, tetrahydropyridine, tetrahydro- pyran, dihydropyran, tetrahydrothiopyran, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydro- pyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolyl, dithi- anyl, dithiolanyl, dihydropyran, tetrahydrothiopyran, tetrahydrofuranyl, pyrazolindinyl, imidazolyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazo- zyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thietyl, isox- azolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzo-furan, cinnol- inyl, indazolyl, indolizinyl, phenazinyl, pyridazinyl, tri- azinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiaz-
olyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). The heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or two oxo (=O) moieties such as pyrrolidin-2-one. Depending on the structure, a heterocycle group can be a monoradical or a diradical (i.e., a heterocyclic group).

The terms “heteroaryl” or, alternatively, “heteroaromatic” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. An N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. Illustrative examples of heteroaryl groups include the following moieties:

Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:

and the like. Depending on the structure, a heteroaryl group can be a monoradical or a diradical (i.e., a heteroarylene group).

As used herein, the term “non-aromatic heterocycle”, “heterocycloalkyl” or “heteroalicyclic” refers to a non-aromatic ring wherein one or more atoms forming the ring is a heteratom. A “non-aromatic heterocycle” or “heterocycloalkyl” group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur. The radicals may be fused with an aryl or heteroaryl. Heterocycloalkyl rings can be formed by three, four, five, six, seven, eight, nine, or more than nine atoms. Heterocycloalkyl rings can be optionally substituted. In certain embodiments, non-aromatic heterocycles contain one or more carbonyl or thio-carbonyl groups such as, for example, o xo- and thio-containing groups. Examples of heterocycloalkyls include, but are not limited to, lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyran, 4H-pyran, tetrahydropyran, piperidine, 1,3-dioxin, 1,3-dioxane, 1,4-dioxin, 1,4-dioxane, and the like. The term heteroalicyclic also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Depending on the structure, a heterocycloalkyl group can be a monoradical or a diradical (i.e., a heterocycloalkylene group).

The term “halo” or, alternatively, “halogen” or “halide” means fluoro, chloro, bromo and iodo.

The terms “haloalkyl,” “haloalkenyl,” “haloalkynyl” and “haloalkoxy” include alkyl, alkenyl, alkynyl and alkoxy structures in which at least one hydrogen is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.

The term “fluoroalkyl,” as used herein, refers to alkyl group in which at least one hydrogen is replaced with
a fluorine atom. Examples of fluoroalkyl groups include, but are not limited to, $\text{–CF}_3$, $\text{–CH}_2\text{CF}_3$, $\text{–CF}_2\text{CF}_3$, $\text{–CH}_2\text{CH}_2\text{CF}_3$ and the like.

[0060] As used herein, the terms “heteroalkyl” “heteroalkenyl” and “heteroalkynyl” include optionally substituted alkyl, alkenyl and alkynyl radicals in which one or more skeletal chain atoms is a heteroatom, e.g., oxygen, nitrogen, sulfur, silicon, phosphorus or combinations thereof. The heteroatom(s) may be placed at any interior position of the heteroalkyl group or at the position at which the heteroalkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, $\text{–CH}_2\text{–O–CH}_3$, $\text{–CH}_2\text{–CH}_2\text{–O–CH}_3$, $\text{–CH}_2\text{–NH–CH}_3$, $\text{–CH}_2\text{–NH–CH}_2\text{–CH}_3$, $\text{–CH}_2\text{–OH}$, $\text{–CH}_2\text{–S–CH}_3$, $\text{–CH}_2\text{–S(O)–CH}_3$, $\text{–CH}_2\text{–S(O)–CH}_2\text{–S(O)–CH}_3$, $\text{–CH}_2\text{–S(O)–CH}_3$, $\text{–CH}_2\text{–N–O–CH}_3$ and $\text{–CH}_2\text{–N–O–CH}_2\text{–S(O)–CH}_3$. In addition, up to two heteroatoms may be consecutive, such as, by way of example, $\text{–CH}_2\text{–NH–O–CH}_3$ and $\text{–CH}_2\text{–O–Si(CH}_3)_2$.

[0061] The term “heteroatom” refers to an atom other than carbon or hydrogen. Heteroatoms are typically independently selected from among oxygen, sulfur, nitrogen, silicon and phosphorus, but are not limited to these atoms. In embodiments in which two or more heteroatoms are present, the two or more heteroatoms can all be the same or one another, or some or all of the two or more heteroatoms can each be different from the others.

[0062] The term “bond” or “single bond” refers to a chemical bond between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure.

[0063] An “isocyanato” group refers to a $\text{–NCO}$ group.

[0064] An “isothiocyanato” group refers to a $\text{–NCS}$ group.

[0065] The term “moiety” refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.

[0066] A “sulfonyl” group refers to a $\text{–S(=O)}$–$\text{–R}$.  
[0067] A “sulfonyl” group refers to a $\text{–SO}_2$–$\text{–R}$.  
[0068] A “thioalkoxy” or “alkythio” group refers to a $\text{–S(=O)}$–$\text{–R}$.  
[0069] A “alkylthioalkyl” group refers to an alkyl group substituted with a $\text{–S(=O)}$–$\text{–R}$.  
[0070] As used herein, the term “O-carboxy” or “acyloxy” refers to a group of formula $\text{RC(=O)O–}$.

[0071] “Carboxy” means a $\text{–C(=O)OH}$ radical.

[0072] As used herein, the term “acetyl” refers to a group of formula $\text{–C(=O)CH}_3$.

[0073] “Acyl” refers to the group $\text{–C(=O)R}$.  
[0074] As used herein, the term “trihalomethanesulfonfyl” refers to a group of formula $\text{X}_3\text{C}$/$\text{S(=O)}$– where $\text{X}$ is a halogen.  
[0075] As used herein, the term “cyanato” refers to a group of formula $\text{–CN}$.

[0076] “Cyanoalkyl” means an alkyl radical, as defined herein, substituted with at least one cyanato group.

[0077] As used herein, the term “N-sulfonylamido” or “sulfonylamido” refers to a group of formula $\text{RS(=O)–NNH–}$.

[0078] As used herein, the term “O-carbamyl” refers to a group of formula $\text{OC(=O)NR}$.

[0079] As used herein, the term “N-carbamyl” refers to a group of formula $\text{ROC(=O)NR}$.

[0080] As used herein, the term “O-thiocarbamyl” refers to a group of formula $\text{OC(=S)NR}$.

[0081] As used herein, the term “N-thiocarbamyl” refers to a group of formula $\text{ROC(=S)NR}$.

[0082] As used herein, the term “C-amido” refers to a group of formula $\text{C(=O)NR}$.

[0083] “Aminocarbonyl” refers to a $\text{–CONH}_2$ radical.

[0084] As used herein, the term “N-amido” refers to a group of formula $\text{RC(=O)NH–}$.

[0085] As used herein, the substituent “R” appearing by itself and without a number designation refers to a substituent selected from among from alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and non-aromatic heterocycle (bonded through a ring carbon).

[0086] The term “optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from among from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, hydroxy, alkoxy, aroyl, aryalkyloxy, aryalklyoxy, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, acyl, nitro, haloalkyl, fluoralkyl, amino, including mono- and di-substituted amino groups, and the protected derivatives thereof. By way of example an optional substituents may be LsRs, wherein each Rs is independently selected from a bond, $\text{–O–}$, $\text{–C(=O)–}$, $\text{–S–}$, $\text{–S(=O)}$–, $\text{–(=O)–}$, $\text{–NH–}$, $\text{–NH(=O)–}$, $\text{–C(=O)NH–}$, $\text{–S(=O)–NH–}$, $\text{–(=O)–NH–}$, $\text{–OC(=O)NH–}$, $\text{–NH(=O)–}$, $\text{–S(=O)–NH–}$, $\text{–OC(=O)NH–}$, $\text{–NH(=O)–}$, $\text{–(=O)–NH–}$, $\text{–O–}$, (substituted or unsubstituted $\text{C}_2\text{–C}_6$ alkyl), or (substituted or unsubstituted $\text{C}_2\text{–C}_6$ alkynyl); and each Rs is independently selected from H, (substituted or unsubstituted $\text{C}_1\text{–C}_4$ alkyl), (substituted or unsubstituted $\text{C}_3\text{–C}_4$ cycloalkyl), heteroaryl, or heteroarylalkyl. The protecting groups that may form the protective derivatives of the above substituents are known to those of skill in the art and may be found in references such as Greene and Wuts, above.

[0087] The term “Michael acceptor moiety” refers to a functional group that can participate in a Michael reaction, wherein a new covalent bond is formed between a portion of the Michael acceptor moiety and the donor moiety. The Michael acceptor moiety is an electrophile and the “donor moiety” is a nucleophile. The “G” groups presented in Formula (I) are non-limiting examples of Michael acceptor moieties.

[0088] The term “nucleophile” or “nucleophilic” refers to an electron rich compound, or moiety thereof. An example of a nucleophile includes, but in no way is limited to, a cysteine residue of a molecule, such as, for example Cys 481 of Btk.

[0089] The term “electrophile”, or “electrophilic” refers to an electron poor or electron deficient molecule, or moiety thereof. Examples of electrophiles include, but in no way are limited to, Michael acceptor moieties.

[0090] The term “acceptable” or “pharmacologically acceptable”, with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated or does not abrogate the biological activity or properties of the compound, and is relatively nontoxic.

[0091] As used herein, the term “agonist” refers to a compound, the presence of which results in a biological activity of a protein that is the same as the biological activity
resulting from the presence of a naturally occurring ligand for the protein, such as, for example, Btk.

[0092] As used herein, the term “partial agonist” refers to a compound the presence of which results in a biological activity of a protein that is of the same type as that resulting from the presence of a naturally occurring ligand for the protein, but of a lower magnitude.

[0093] As used herein, the term “antagonist” refers to a compound, the presence of which results in a decrease in the magnitude of a biological activity of a protein. In certain embodiments, the presence of an antagonist results in complete inhibition of a biological activity of a protein, such as, for example, Btk. In certain embodiments, an antagonist is an inhibitor.

[0094] As used herein, “amelioration” of the symptoms of a particular disease, disorder or condition by administration of a particular compound or pharmaceutical composition refers to any lessening of severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the compound or composition.

[0095] “Bioavailability” refers to the percentage of the weight of compounds disclosed herein, such as compounds of Formula (1), dosed that is delivered into the general circulation of the animal or human being studied. The total exposure (AUC(0-∞)) of a drug when administered intravenously is usually defined as 100% bioavailable (F %). “Oral bioavailability” refers to the extent to which compounds disclosed herein, such as compounds of any of Formula (1), are absorbed into the general circulation when the pharmaceutical composition is taken orally as compared to intravenous injection.

[0096] “Blood plasma concentration” refers to the concentration of compounds disclosed herein, such as compounds of Formula (1), in the plasma component of blood of a subject. It is understood that the plasma concentration of compounds of Formula (1) may vary significantly between subjects, due to variability with respect to metabolism and/or possible interactions with other therapeutic agents. In accordance with one embodiment disclosed herein, the blood plasma concentration of the compounds Formula (1), may vary from subject to subject. Likewise, values such as maximum plasma concentration (Cmax) or time to reach maximum plasma concentration (Tmax), or total area under the plasma concentration time curve (AUC(0-∞)) may vary from subject to subject. Due to this variability, the amount necessary to constitute “a therapeutically effective amount” of a compound of Formula (1) may vary from subject to subject.

[0097] The term “Bruton’s tyrosine kinase,” as used herein, refers to Bruton’s tyrosine kinase from Homo sapiens; as disclosed in, e.g., U.S. Pat. No. 6,326,469 (GenBank Accession No. NP-000055).

[0098] The term “Bruton’s tyrosine kinase homolog,” as used herein, refers to orthologs of Bruton’s tyrosine kinase, e.g., the orthologs from mouse (GenBank Accession No. AAB47246), dog (GenBank Accession No. XP-549139), rat (GenBank Accession No. NP-001007709), chicken (GenBank Accession No. NP-089564), or zebrafish (GenBank Accession No. XP-698117), and fusion proteins of any of the foregoing that exhibit kinase activity towards one or more substrates of Bruton’s tyrosine kinase (e.g. a peptide substrate having the amino acid sequence “AVLESEEELYSSARQ”).

[0099] The terms “co-administration” or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration, or at the same or different time.

[0100] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition including a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms without undue adverse side effects. An appropriate “effective amount” in any individual case may be determined using techniques, such as a dose escalation study. The term “therapeutically effective amount” includes, for example, a prophylactically effective amount. An “effective amount” of a compound disclosed herein is an amount effective to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects. It is understood that “an effective amount” or “a therapeutically effective amount” can vary from subject to subject, due to variation in metabolism of the compound of Formula (1), age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. By way of example only, therapeutically effective amounts may be determined by routine experimentation, including but not limited to a dose escalation clinical trial.

[0101] The terms “enhance” or “enhancing” means to increase or prolong either in potency or duration a desired effect. By way of example, “enhancing” the effect of therapeutic agents refers to the ability to increase or prolong, either in potency or duration, the effect of therapeutic agents on during treatment of a disease, disorder or condition. An “enhancing-effective amount,” as used herein, refers to an amount adequate to enhance the effect of a therapeutic agent in the treatment of a disease, disorder or condition. When used in a patient, amounts effective for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient’s health status and response to the drugs, and the judgment of the treating physician.

[0102] The term “homologous cysteine,” as used herein refers to a cysteine residue found with in a sequence position that is homologous to that of cysteine 481 of Bruton’s tyrosine kinase, as defined herein. For example, cysteine 482 is the homologous cysteine of the rat ortholog of Bruton’s tyrosine kinase; cysteine 479 is the homologous cysteine of the chicken ortholog; and cysteine 481 is the homologous cysteine in the zebrafish ortholog. In another example, the homologous cysteine of TK4, a Tec kinase family member related to Bruton’s tyrosine, is Cys 350. See also the sequence alignments of tyrosine kinases (TK) published on the world wide web at kinase.com/human/kinome/phylogeny.html.
The term "identical," as used herein, refers to two or more sequences or subsequences which are the same. In addition, the term "substantially identical," as used herein, refers to two or more sequences which have a percentage of sequential units which are the same when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using comparison algorithms or by manual alignment and visual inspection. By way of example only, two or more sequences may be "substantially identical" if the sequential units are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a specified region. Such percentages to describe the "percent identity" of two or more sequences. The identity of a sequence can exist over a region that is at least about 75-100 sequential units in length, over a region that is about 50 sequential units in length, or, where not specified, across the entire sequence. This definition also refers to the complement of a test sequence. By way of example only, two or more polypeptide sequences are identical when the amino acid residues are the same, while two or more polypeptide sequences are "substantially identical" if the amino acid residues are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a specified region. The identity can exist over a region that is at least about 75-100 amino acids in length, over a region that is about 50 amino acids in length, or, where not specified, across the entire sequence of a polypeptide sequence. In addition, by way of example only, two or more polynucleotide sequences are identical when the nucleic acid residues are the same, while two or more polynucleotide sequences are "substantially identical" if the nucleic acid residues are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a specified region. The identity can exist over a region that is at least about 75-100 nucleic acids in length, over a region that is about 50 nucleic acids in length, or, where not specified, across the entire sequence of a polynucleotide sequence.

The terms "inhibits", "inhibiting", or "inhibitor" of a kinase, as used herein, refer to inhibition of enzymatic phosphotransferase activity.

The term "irreversible inhibitor," as used herein, refers to a compound that, upon contact with a target protein (e.g., a kinase) causes the formation of a new covalent bond with or within the protein, whereby one or more of the target protein's biological activities (e.g., phosphotransferase activity) is diminished or abolished notwithstanding the subsequent presence or absence of the irreversible inhibitor.

The term "irreversible Btk inhibitor," as used herein, refers to an inhibitor of Btk that can form a covalent bond with an amino acid residue of Btk. In one embodiment, the irreversible inhibitor of Btk can form a covalent bond with a Cys residue of Btk; in particular embodiments, the irreversible inhibitor can form a covalent bond with a Cys 481 residue (or a homolog thereof) of Btk or a cysteine residue in the homologous corresponding position of another tyrosine kinase.

The term "isolated," as used herein, refers to separating and removing a component of interest from components not of interest. Isolated substances can be in either a dry or semi-dry state, or in solution, including but not limited to an aqueous solution. The isolated component can be in a homogeneous state or the isolated component can be a part of a pharmaceutical composition that comprises additional pharmaceutically acceptable carriers and/or excipients. By way of example only, nucleic acids or proteins are "isolated" when such nucleic acids or proteins are free of at least some of the cellular components with which it is associated in the natural state, or that the nucleic acid or protein has been concentrated to a level greater than the concentration of its in vivo or in vitro production. Also, by way of example, a gene is isolated when separated from open reading frames which flank the gene and encode a protein other than the gene of interest.

A "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. The term "active metabolite" refers to a biologically active derivative of a compound that is formed when the compound is metabolized. The term "metabolized," as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes, such as, oxidation reactions) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound. For example, cytochrome P450 catalyzes a variety of oxidative and reductive reactions while uridine diphosphate glucuronyl transferases catalyze the transfer of an activated glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulfhydryl groups. Further information on metabolism may be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites of the compounds disclosed herein can be identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds. Both methods are well known in the art. In some embodiments, metabolites of a compound are formed by oxidative processes and correspond to the corresponding hydroxy-containing compound. In some embodiments, a compound is metabolized to pharmacologically active metabolites.

The term "modulate," as used herein, means to interact with a target either directly or indirectly so as to alter the activity of the target, including by way of example only, to enhance the activity of the target, to inhibit the activity of the target, to limit the activity of the target, or to extend the activity of the target.

As used herein, the term "modulator" refers to a compound that alters an activity of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a certain activity of a molecule compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of one or more activities of a molecule. In certain embodiments, an inhibitor completely prevents one or more activities of a molecule. In certain embodiments, a modulator is an activator, which increases the magnitude of at least one activity of a molecule. In certain embodiments the presence of a modulator results in an activity that does not occur in the absence of the modulator.

The term "prophylactically effective amount," as used herein, refers that amount of a composition applied to
a patient which will relieve to some extent one or more of the symptoms of a disease, condition or disorder being treated. In such prophylactic applications, such amounts may depend on the patient's state of health, weight, and the like. It is considered well within the skill of the art for one to determine such prophylactically effective amounts by routine experimentation, including, but not limited to, a dose escalation clinical trial.

As used herein, the term “selective binding compound” refers to a compound that selectively binds to any portion of one or more target proteins.

As used herein, the term “selectively binds” refers to the ability of a selective binding compound to bind to a target protein, such as, for example, Btk, with greater affinity than it binds to a non-target protein. In certain embodiments, specific binding refers to binding to a target with an affinity that is at least 10, 50, 100, 250, 500, 1000 or more times greater than the affinity for a non-target.

As used herein, the term “selective modulator” refers to a compound that selectively modulates a target activity relative to a non-target activity. In certain embodiments, specific modulator refers to modulating a target activity at least 10, 50, 100, 250, 500, 1000 times more than a non-target activity.

The term “substantially purified,” as used herein, refers to a component of interest that may be substantially or essentially free of other components which normally accompany or interact with the component of interest prior to purification. By way of example only, a component of interest may be “substantially purified” when the preparation of the component of interest contains less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminants components. Thus, a “substantially purified” component of interest may have a purity level of about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or greater.

The term “subject” as used herein, refers to an animal which is the object of treatment, observation or experiment. By way of example only, a subject may be, but is not limited to, a mammal including, but not limited to, a human.

As used herein, the term “target activity” refers to a biological activity capable of being modulated by a selective modulator. Certain exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzymatic activity, tumor growth, inflammation or inflammation-related processes, and amelioration of one or more symptoms associated with a disease or condition.

As used herein, the term “target protein” refers to a molecule or a portion of a protein capable of being bound by a selective binding compound. In certain embodiments, a target protein is Btk.

The terms “treat,” “treating” or “treatment”, as used herein, include alleviating, abating or ameliorating a disease or condition symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition. The terms “treat,” “treating” or “treatment”, include, but are not limited to, prophylactic and/or therapeutic treatments.

As used herein, the IC_{50} refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response, such as inhibition of Btk, in an assay that measures such response.

As used herein, EC_{50} refers to a dosage, concentration or amount of a particular test compound that elicits a dose-dependent response at 50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.

**Compounds**

Certain embodiments provide a compound of Formula (I):

```
  R¹-R¹⁺, R²-R²⁺, R³-R³⁺, R⁴-R⁴⁺, R⁵-R⁵⁺, R⁶-R⁶⁺,
```

or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein:

- A is selected from N and CR;
- each R¹, R², R³, R⁴, and R⁵ is independently selected from H, halogen, -CF₃, -CN, -NO₂, OH, NH₂, -L₁-(substituted or unsubstituted alkyl), -L₁-(substituted or unsubstituted alkenyl), -L₁-(substituted or unsubstituted heteroaryl), or -L₁-(substituted or unsubstituted aryl), wherein L is a bond, O, S, -S(=O)-, -S(=O)=, -NH-, -C(O)-, -CH₂-, -NHCO(O)O-, -NHCO(O)-, or -C(O)NH;
- R² is selected from H and lower alkyl;
- R³ is L²-X-L³-G, wherein:
- L² is selected from a bond, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenylene, and substituted or unsubstituted alkylenylene;
- X is selected from a bond, O, -C(=O)-, S, -S(=O)-, -S(=O)=, -NH-, -NR₄⁺, -NHC(=O)H-, -NR₁⁴⁺-(C(O))NR¹⁴⁺, -S(=O)₂NH₂, -NH₂S(=O)=, -S(=O)=, -OC(O)NH-, -NHC(O)O-, -OC(O)NR¹⁴⁺, -NR₁⁴⁺C(=O)NR¹⁴⁺, -CH₂NO-, -ON-CH₂-, -NR⁵⁺(C(O))NR⁵⁺, -heteroaryl, -NR¹⁴⁺C(=N)=, -C(=N)(NR¹⁴⁺)=, -OC(=NR¹⁴⁺), and -C(=NR¹⁴⁺)=, wherein
- R¹⁴⁺ is selected from H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl,
[0130] each R₁⁵ is independently selected from H, substituted or unsubstituted lower alkyl, and substituted or unsubstituted lower cycloalkyl; and

[0131] R₁⁶ is selected from H, —S(==O)₂R¹¹, —S(==O)₂NH₂, —C(O)R¹¹, —CN, —NO₂, heteroaryl, and heteroalkyl;

[0132] L₃ is selected from a bond, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkenyl, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, and substituted or unsubstituted heterocyclicene;

[0133] or L², X and L₃ taken together form a nitrogen containing heterocyclic ring; and

[0134] G is selected from the following structures:

```
O R₁₁ O
```

and

Z is selected from the following structures:

```
O R₁₁ O
```

[0135] wherein each R¹¹, R¹², and R¹³ is independently selected from H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl.

[0136] In certain embodiments of a compound of Formula (I), A is selected from N and CR¹¹, wherein R¹¹ is selected from H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower aryl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl.

[0137] In certain embodiments of a compound of Formula (I), A is N.

[0138] In certain embodiments of a compound of Formula (I), A is CR¹¹, wherein R¹¹ is selected from H, methyl, ethyl, n-propyl, cyclopentyl, cyclohexyl, phenyl, and benzyl.

[0139] In certain embodiments of a compound of Formula (I), A is CR¹¹, wherein R¹¹ is H.

[0140] In certain embodiments of a compound of Formula (I), each R¹ is independently selected from H, halogen, —CF₃, —CN, —NO₂, OH, and NH₃.

[0141] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H, —L¹-(substituted or unsubstituted alkyl), —L¹-(substituted or unsubstituted heteroalkyl), and —L¹-(substituted or unsubstituted aryl), wherein L¹ is selected from a bond, O, S, —S(==O)₂, —NH—, —C(O)O—, —C(O)NH—, —NHCOO—, —NHCO—, —CO—, and —NH—,

[0142] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H, —L¹-(substituted or unsubstituted alkyl), —L¹-(substituted or unsubstituted heteroalkyl), —L¹-(substituted or unsubstituted aryl), wherein L¹ is selected from a bond, O, and NH.

[0143] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H, —L¹-(substituted or unsubstituted alkyl), —L¹-(substituted or unsubstituted heteroalkyl), and —L¹-(substituted or unsubstituted aryl), wherein L¹ is O.

[0144] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H and —L¹-(substituted or unsubstituted phenyl), wherein L¹ is O.

[0145] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H and —O-phenyl.

[0146] In certain embodiments of a compound of Formula (I), each R¹⁴, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ is independently selected from H and —O-phenyl.

[0147] In certain embodiments of a compound of Formula (I), R² is selected from H and lower alkyl.

[0148] In certain embodiments of a compound of Formula (I), R² is selected from H, methyl, ethyl, n-propyl, and isopropyl.

[0149] In certain embodiments of a compound of Formula (I), R² is selected from H and methyl.

[0150] In certain embodiments of a compound of Formula (I), R² is H.

[0151] In certain embodiments of a compound of Formula (I), R² is L²-X-L²-G₁.

[0152] In certain embodiments of a compound of Formula (I), L² is selected from a bond, substituted or unsubstituted alkenylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted alkenyl, and substituted or unsubstituted alkenylene.

[0153] In certain embodiments of a compound of Formula (I), L² is selected from a bond, methylene, ethylene, propylene, butylene, cyclopentylene, and cyclohexylene.

[0154] In certain embodiments of a compound of Formula (I), X is selected from a bond, O, —C(==O)—, S,
In certain embodiments of a compound of Formula (I), L^2 is a bond.

In certain embodiments of a compound of Formula (I), L^2 is a bond and X is a bond.

In certain embodiments of a compound of Formula (I), L^2 is a bond and X is a bond.

In certain embodiments of a compound of Formula (I), L^2 is selected from a bond, substituted or unsubstituted alkyne, substituted or unsubstituted cycloalkyne, substituted or unsubstituted alkenylene, substituted or unsubstituted alkenylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, and substituted or unsubstituted heterocyclic ring.

In certain embodiments of a compound of Formula (I), L^2 is selected from a bond, methylene, ethylene, propylene, butylene, cyclopentylene, cyclohexylene, phenylene, piperidylene, and pyrrolidinylene.

In certain embodiments of a compound of Formula (I), L^2 is selected from a bond, 1,2-piperidylene, 1,3-piperidylene, and 1,4-piperidylene.

In certain embodiments of a compound of Formula (I), L^2 is selected from the following structures:

In certain embodiments of a compound of Formula (I), L^2, X and L^3 taken together form a nitrogen containing heterocyclic ring.

In certain embodiments of a compound of Formula (I), L^2, X and L^3 taken together form a nitrogen containing heterocyclic ring selected from the following structures:
wherein each \( R^{11} \), \( R^{12} \), and \( R^{13} \) is independently selected from \( H \), methyl, ethyl, \( n \)-propyl, isopropyl, \( 2-(\text{dimethylamino})\text{ethyl} \), \( (\text{dimethylamino})\text{methyl} \), methoxymethyl, cyclohexyl, and phenyl.

In certain embodiments of a compound of Formula (I), \( G \) is selected from the following structures:

[0168] In certain embodiments of a compound of Formula (I), \( G \) is selected from the following structures:

[0170] In certain embodiments of a compound of Formula (I), \( G \) is selected from the following structures:

wherein each \( R^{11} \), \( R^{12} \), and \( R^{13} \) is independently selected from \( H \), substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl.

[0169] In certain embodiments of a compound of Formula (I), \( G \) is selected from the following structures:

[0171] In certain embodiments of a compound of Formula (I), \( R^3 \) is selected from the following structures:
[0173] In certain embodiments of a compound of Formula (I), R is the following structure:

\[
\text{Structure A}
\]

[0174] In certain embodiments of a compound of Formula (I), Z is selected from the following structures:

\[
\text{Structure B}
\]

\[
\text{Structure C}
\]

\[
\text{Structure D}
\]

wherein each \( R^{11}, R^{12}, \) and \( R^{13} \) is independently selected from \( H, \) substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl.

[0175] In certain embodiments of a compound of Formula (I), Z is selected from the following structures:

\[
\text{Structure E}
\]

\[
\text{Structure F}
\]
wherein each R¹¹, R¹², and R¹³ is independently selected from H, methyl, ethyl, n-propyl, isopropyl, isobutyl, tert-butyl, pentyl, neopentyl, n-hexyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, phenyl, and benzyl.

[0176] In certain embodiments of a compound of Formula (I), Z is selected from the following structures:
In certain embodiments of a compound of Formula (I), Z is selected from the following structures:

[0177]

[0178] In certain embodiments of a compound of Formula (I), Z is selected from the following structures:

[0179] In certain embodiments of a compound of Formula (I), Z is selected from the following structures:
In certain embodiments of a compound of Formula (I), A is N; each \( R^{1a} \), \( R^{1b} \), \( R^{1c} \), \( R^{1d} \) and \( R^{1e} \) is independently selected from H and \(-O\text{-phenyl}; \) \( R^2 \) is H;

\[ R^3 \] is

![Chemical structure](image1)

and \( Z \) is

![Chemical structure](image2)


![Chemical structure](image3)
In certain embodiments of a compound of Formula (I), the compound is chosen from a compound of Formula (I-C-1) and Formula (I-C-2):

![Chemical structure](image1)

In certain embodiments of a compound of Formula (I), the compound is chosen from a compound of Formula (I-B-1) and Formula (I-B-2):

![Chemical structure](image2)

Compounds disclosed herein may be obtained via the synthetic methods illustrated in Schemes I-A and I-B. General synthetic methods useful in the synthesis of compounds described herein are available in the art. Starting materials useful for preparing compounds and intermediates thereof and/or practicing methods described herein are commercially available or can be prepared by well-known synthetic methods. The methods presented in the schemes provided by the present disclosure are illustrative rather than comprehensive. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the disclosure.
Ibrutinib prodrugs of Formula (I) can be prepared according to Schemes I-A and I-B:

**Scheme I-A**

**Scheme I-B**

-continued
Pharmaceutical Compositions

[0194] Pharmaceutical compositions provided by the present disclosure may comprise a therapeutically effective amount of a compound of Formula (I) together with a suitable amount of one or more pharmaceutically acceptable vehicles so as to provide a composition for proper administration to a patient. Suitable pharmaceutical vehicles are described in the art.

[0195] In certain embodiments, a compound of Formula (I) may be incorporated into pharmaceutical compositions to be administered orally. Oral administration of such pharmaceutical compositions may result in uptake of a compound of Formula (I) throughout the intestine and entry into the systemic circulation. Such oral compositions may be prepared in a manner known in the pharmaceutical art and comprise a compound of Formula (I) and at least one pharmaceutically acceptable vehicle. Oral pharmaceutical compositions may include a therapeutically effective amount of a compound of Formula (I) and a suitable amount of a pharmaceutically acceptable vehicle, so as to provide an appropriate form for administration to a patient.

[0196] Compounds of Formula (I) may be incorporated into pharmaceutical compositions to be administered by any other appropriate route of administration including intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, inhalation, or topical.

[0197] Pharmaceutical compositions comprising a compound of Formula (I) and may be manufactured by means of conventional mixing dissolving granulating dragee-making levigating emulsifying encapsulating entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients, or auxiliaries, which facilitate processing of compounds of Formula (I) or crystalline forms thereof and one or more pharmaceutically acceptable vehicles into formulations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Pharmaceutical compositions provided by the present disclosure may take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for administration to a patient.

[0198] Pharmaceutical compositions provided by the present disclosure may be formulated in a unit dosage form. A unit dosage form refers to a physically discrete unit suitable as a unitary dose for patients undergoing treatment, with each unit containing a predetermined quantity of a compound of Formula (I) calculated to produce an intended therapeutic effect. A unit dosage form may be for a single daily dose, for administration 2 times per day, or one of multiple daily doses, e.g., 3 or more times per day. When multiple daily doses are used, a unit dosage form may be the same or different for each dose. One or more dosage forms may comprise a dose, which may be administered to a patient at a single point in time or during a time interval.

[0199] Pharmaceutical compositions comprising a compound of Formula (I) may be formulated for immediate release.

[0200] In certain embodiments, an oral dosage form provided by the present disclosure may be a controlled release dosage form. Controlled delivery technologies can improve the absorption of a drug in a particular region or regions of the gastrointestinal tract. Controlled drug delivery systems may be designed to deliver a drug in such a way that the drug level is maintained within a therapeutically effective window and effective and safe blood levels are maintained for a period as long as the system continues to deliver the drug with a particular release profile in the gastrointestinal tract. Controlled drug delivery may produce substantially constant blood levels of a drug over a period of time as compared to fluctuations observed with immediate release dosage forms. For some drugs, maintaining a constant blood and tissue concentration throughout the course of therapy is the most desirable mode of treatment. Immediate release of drugs may cause blood levels to peak above the level required to elicit a desired response, which may waste the drug and may cause or exacerbate toxic side effects. Controlled drug delivery can result in optimum therapy, and not only can reduce the frequency of dosing, but may also reduce the severity of side effects. Examples of controlled release dosage forms include dissolution controlled systems, diffusion controlled systems, ion exchange resins, osmotically controlled systems, erodable matrix systems, pH independent formulations, gastric retention systems, and the like.

[0201] An appropriate oral dosage form for a particular pharmaceutical composition provided by the present disclosure may depend, at least in part, on the gastrointestinal absorption properties of a compound of Formula (I) the stability of a compound of Formula (I) in the gastrointestinal tract, the pharmacokinetics of a compound of Formula (I) and the intended therapeutic profile. An appropriate controlled release oral dosage form may be selected for a particular compound of Formula (I). For example, gastric retention oral dosage forms may be appropriate for compounds absorbed primarily from the upper gastrointestinal tract, and sustained release oral dosage forms may be appropriate for compounds absorbed primarily from the lower gastrointestinal tract. Certain compounds are absorbed primarily from the small intestine. In general, compounds traverse the length of the small intestine in about 3 to 5 hours. For compounds that are not easily absorbed by the small intestine or that do not dissolve readily, the window for active agent absorption in the small intestine may be too short to provide a desired therapeutic effect.

[0202] In certain embodiments, pharmaceutical compositions provided by the present disclosure may be practiced with dosage forms adapted to provide sustained release of a compound of Formula (I) upon oral administration. Sustained release oral dosage forms may be used to release drugs over a prolonged time period and are useful when it is desired that a drug or drug form be delivered to the lower gastrointestinal tract. Sustained release oral dosage forms include any oral dosage form that maintains therapeutic concentrations of a drug in a biological fluid such as the plasma, blood, cerebrospinal fluid, or in a tissue or organ for a prolonged time period. Sustained release oral dosage forms include diffusion-controlled systems such as reservoir devices and matrix devices, dissolution-controlled systems, osmotic systems, and erosion-controlled systems. Sustained release oral dosage forms and methods of preparing the same are well known in the art.

[0203] An appropriate dose of a compound of Formula (I) or pharmaceutical composition comprising a compound of Formula (I) may be determined according to any one of several well-established protocols. For example, animal
studies such as studies using mice, rats, dogs, and/or mon- 
keys may be used to determine an appropriate dose of a 
pharmaceutical compound. Results from animal studies may 
be extrapolated to determine doses for use in other species, 
such as for example, humans.

Uses

[0204] The methods described herein include administering 
to a subject in need a composition containing a therapeu-
tically effective amount of one or more irreversible Btk 
inhibitor compounds described herein. Without being bound 
by theory, the diverse roles played by Btk signaling in 
various hematopoietic cell functions, e.g., B-cell receptor 
activation, suggests that small molecule Btk inhibitors are 
useful for reducing the risk of or treating a variety of 
diseases affected by or affecting many cell types of the 
hematopoietic lineage including, e.g., autoimmune diseases, 
heteroimmune conditions or diseases, inflammatory dis-
ces, cancer (e.g., B-cell proliferative disorders), and 
thromboembolic disorders. Further, the irreversible Btk 
inhibitor compounds described herein can be used to inhibit 
a small subset of other tyrosine kinases that share homology 
with Btk by having a cysteine residue (including a Cys 481 
residue) that can form a covalent bond with the irreversible 
inhibitor. Thus, a subset of tyrosine kinases other than Btk 
are also expected to be useful as therapeutic targets in a 
number of health conditions.

[0205] In some embodiments, the methods described 
herein can be used to treat an autoimmune disease, which 
includes, but is not limited to, rheumatoid arthritis, psoriatic 
arthritis, osteoarthritis, Still’s disease, juvenile arthritis, lupus, diabetes, myasthenia gravis, Hashimoto’s thyroiditis, 
Omd’s thyroiditis, Graves’ disease, Sjögren’s syndrome, 
multiple sclerosis, Guillain-Barré syndrome, autoimmune 
disease, ankylosing spondylitis, antiphospholipid antibody 
syndrome, aplastic anemia, autoimmunity hepatitis, coeliac disease, Goodpasture’s syndrome, idiopathic 
thrombocytopenic purpura, optic neuritis, scleroderma, 
primary biliary cirrhosis, Reiter’s syndrome, Takaya-
su’s arteritis, temporal arteritis, warm autoimmunity 
hematologic anemia, Wegener’s granulomatosis, psoriasis, 
alopexia universalis, Behcet’s disease, chronic fatigue, dys-
autonomia, endometriosis, interstitial cystitis, neuror- 
oneurology, scleroderma, and vulvodynia.

[0206] In some embodiments, the methods described 
herein can be used to treat heteroimmune conditions or 
diseases, which include, but are not limited to graft versus 
host disease, transplantation, transfusion, anaphylaxis, allergies 
(e.g., allergies to plant pollens, latex, drugs, foods, 
pesticides, animal hair, animal dander, dust mites, or 
cockroach dander), type I hypersensitivity, allergic conjunc-
tivitis, allergic rhinitis, and atopic dermatitis.

[0207] In further embodiments, the methods described 
herein can be used to treat an inflammatory disease, which 
includes, but is not limited to asthma, inflammatory bowel 
disease, appendicitis, blepharitis, bronchiolitis, bronchitis, 
bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermato-
myositis, encephalitis, endocarditis, endometriosis, enteritis, 
teratoctis, episcleritis, epidermolysis, fasciitis, fibrositis, 
gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, 
lymphitis, mastitis, meningitis, myelitis myocarditis, myo-
itis, nephritis, ophthalmitis, orchitis, osteitis, otitis, pancrea-
titis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, 
phlebitis, pneumonia, pneumonitis, psoriasis, proctitis, prostatitis, 
pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, 
synovitis, tendinitis, tonsillitis, iveritis, vaginitis, vasculitis, 
and vulvitis.

[0208] In yet other embodiments, the methods described 
herein can be used to treat a cancer, e.g., B-cell proliferative 
disorders, which include, but are not limited to diffuse large 
B cell lymphoma, follicular lymphoma, chronic lympho-
cytic lymphoma, chronic lymphocytic leukemia, chronic 
lymphocytic leukemia with 17p deletion, B-cell prolympho-
cytic leukemia, lymphoplasmacytoid lymphoma/Walden-
ström macroglobulinemia, splenic marginal zone lym-
phoma, plasma cell myeloma, plasmacytoma, extranodal 
marginal zone B cell lymphoma, nodal marginal zone B cell 
lymphoma, mantle cell lymphoma, mediastinal (thymic) 
large B cell lymphoma, intravascular large B cell lymphoma, 
primary effusion lymphoma, Burkitt lymphoma/leukemia, 
and lymphomatomat granulomatosis.

[0209] In further embodiments, the methods described 
herein can be used to treat thromboembolic disorders, which 
include, but are not limited to myocardial infarct, angina 
pectoris (including unstable angina), reocclusions or rest-
oses after angioplasty or aortocoronary bypass, stroke, 
transitory ischemia, peripheral arterial occlusive disorders, 
pulmonary embolisms, and deep venous thromboses.

[0210] Symptoms, diagnostic tests, and prognostic tests 
for each of the above-mentioned conditions are known in the 
(2006). Cytojournal 3(24), and the “Revised American 
Lymphoma” (REAL) classification system (see, 
e.g., the website maintained by the National Cancer Insti-
tute).

[0211] A number of animal models of are useful for 
establishing a range of therapeutically effective doses of 
irreversible Btk inhibitor compounds for treating any of 
the foregoing diseases.

[0212] For example, dosing of irreversible Btk inhibitor 
compounds for treating an autoimmune disease can be 
assessed in a mouse model of rheumatoid arthritis. In this 
model, arthritis is induced in Balb/c mice by administering 
anti-collagen antibodies and lipopolysaccharide. See Nand-
alan et al. (2003), Am. J. Pathol. 163:1801-1807.

[0213] In another example, dosing of irreversible Btk 
inhibitors for the treatment of B-cell proliferative disorders 
can be examined in, e.g., a human-to-mouse xenograft 
model in which human B-cell lymphoma cells (e.g. Ramos 
cells) are implanted into immunodeficient mice (e.g., “nude” 
mice) as described in, e.g., Pagel et al. (2005), Clin Cancer 

Animal models for treatment of thromboembolic disorders 
are also known.

[0214] The therapeutic efficacy of the compound for one 
of the foregoing diseases can be optimized during a course 
of treatment. For example, a subject being treated can 
undergo a diagnostic evaluation to correlate the relief of 
disease symptoms or pathologies to inhibition of in vivo Btk 
activity achieved by administering a given dose of an 
irreversible Btk inhibitor. Cellular assays known in the art 
can be used to determine in vivo activity of Btk in the 
presence or absence of an irreversible Btk inhibitor. For 
example, since activated Btk is phosphorylated at tyrosine 
223 (Y223) and tyrosine 551 (Y551), phospho-specific
immunocytochemical staining of P-Y223 or P-Y551-positive cells can be used to detect or quantify activation of Btk in a population of cells (e.g., by FACS analysis of stained vs unstained cells). See, e.g., Nisitani et al. (1999), Proc. Natl. Acad. Sci, USA 96:2221-2226. Thus, the amount of the Btk inhibitor inhibitor compound that is administered to a subject can be increased or decreased as needed so as to maintain a level of Btk inhibition optimal for treating the subject’s disease state.

Administration

[0215] Compounds of Formula (I) and pharmaceutical compositions thereof may be administered orally or by any other appropriate route, for example, by infusion or bolus injection, by absorption through epithelial or muco-cutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa, etc.). Other suitable routes of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidermal, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, inhalation, or topical.

[0216] Administration may be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc. that may be used to administer a compound and/or pharmaceutical composition.

[0217] The amount of a compound of Formula (I) that will be effective in the treatment of a disease in a patient will depend, in part, on the nature of the condition and can be determined by standard clinical techniques known in the art. In addition, in vitro or in vivo assays may be employed to help identify optimal dosage ranges. A therapeutically effective amount of a compound of Formula (I) to be administered may also depend on, among other factors, the subject being treated, the weight of the subject, the severity of the disease, the manner of administration, and the judgment of the prescribing physician.

[0218] For systemic administration, a therapeutically effective dose may be estimated initially from in vitro assays. For example, a dose may be formulated in animal models to achieve a beneficial circulating composition concentration range. Initial doses may also be estimated from in vivo data, e.g., animal models, using techniques that are known in the art. Such information may be used to more accurately determine useful doses in humans. One having ordinary skill in the art may optimize administration to humans based on animal data.

[0219] A dose may be administered in a single dosage form or in multiple dosage forms. When multiple dosage forms are used the amount of compound contained within each dosage form may be the same or different. The amount of a compound of Formula (I) contained in a dose may depend on the route of administration and whether the disease in a patient is effectively treated by acute, chronic, or a combination of acute and chronic administration.

[0220] In certain embodiments an administered dose is less than a toxic dose. Toxicity of the compositions described herein may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD<sub>50</sub> (the dose lethal to 50% of the population) or the LD<sub>100</sub> (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. In certain embodiments, a compound of Formula (I) may exhibit a high therapeutic index. The data obtained from these cell culture assays and animal studies may be used in formulating a dosage range that is not toxic for use in humans. A dose of a compound of Formula (I) provided by the present disclosure may be within a range of circulating concentrations in for example the blood, plasma, or central nervous system, that include the effective dose and that exhibits little or no toxicity. A dose may vary within this range depending upon the dosage form employed and the route of administration utilized. In certain embodiments, an escalating dose may be administered.

Combination Therapy

[0221] The irreversible Btk inhibitor compositions described herein can also be used in combination with other well known therapeutic reagents that are selected for their therapeutic value for the condition to be treated. In general, the compositions described herein and, in embodiments where combinational therapy is employed, other agents do not have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, have to be administered by different routes. The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician. The initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.

[0222] In certain instances, it may be appropriate to administer at least one irreversible Btk inhibitor compound described herein in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the irreversible Btk inhibitor compounds described herein is nausea, then it may be appropriate to administer an anti-nausea agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Or, by way of example only, the benefit experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.

[0223] The particular choice of compounds used will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol. The compounds may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the disease, disorder, or condition, the condition of the patient, and the actual choice of compounds used. The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment
protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient.

[0224] It is known to those of skill in the art that therapeutically-effective dosages can vary when the drugs are used in treatment combinations. Methods for experimentally determining therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens are described in the literature. For example, the use of metronomic dosing i.e., providing more frequent, lower doses in order to minimize toxic side effects, has been described extensively in the literature. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.

[0225] For combination therapies described herein, dosages of the co-administered compounds will of course vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated and so forth. In addition, when co-administered with one or more biologically active agents, the compound provided herein may be administered either simultaneously with the biologically active agent(s), or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein in combination with the biologically active agent(s).

[0226] In any case, the multiple therapeutic agents (one of which is a compound of Formula (I) described herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may vary from more than zero weeks to less than four weeks. In addition, the combination methods, compositions and formulations are not to be limited to the use of only two agents; the use of multiple therapeutic combinations are also envisioned.

[0227] It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, can be modified in accordance with a variety of factors. These factors include the disorder from which the subject suffers, as well as the age, weight, sex, diet, and medical condition of the subject. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the dosage regimens set forth herein.

[0228] The pharmaceutical agents which make up the combination therapy disclosed herein may be a combined dosage form or in separate dosage forms intended for substantially simultaneous administration. The pharmaceutical agents that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration. The two-step administration regimen may call for sequential administration of the active agents or spaced-apart administration of the separate active agents. The time period between the multiple administration steps may range from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent. Circadian variation of the target molecule concentration may also determine the optimal dose interval.

[0229] In addition, the compounds described herein also may be used in combination with procedures that may provide additional or synergistic benefit to the patient. By way of example only, patients are expected to find therapeutic and/or prophylactic benefit in the methods described herein, wherein pharmaceutical composition of a compound disclosed herein and/or combinations with other therapeutic agents are combined with genetic testing to determine whether that individual is a carrier of a mutant gene that is known to be correlated with certain diseases or conditions.

[0230] The compounds described herein and combination therapies can be administered before, during or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound can vary. Thus, for example, the compounds can be used as a prophylactic and can be administered continuously to subjects with a propensity to develop conditions or diseases in order to prevent the occurrence of the disease or condition. The compounds and compositions can be administered to a subject during or as soon as possible after the onset of the symptoms. The administration of the compounds can be initiated within the first 48 hours of the onset of the symptoms, within the first 6 hours of the onset of the symptoms, or within 3 hours of the onset of the symptoms. The initial administration can be via any route practical, such as, for example, an intravenous injection, a bolus injection, infusion over 5 minutes to about 5 hours, a pill, a capsule, transdermal patch, buccal delivery, and the like, or combination thereof. A compound should be administered as soon as is practicable after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months. The length of treatment can vary for each subject, and the length can be determined using the known criteria. For example, the compound or a formulation containing the compound can be administered for at least 2 weeks, between about 1 month to about 5 years, or from about 1 month to about 3 years.

Exemplary Therapeutic Agents for Use in Combination with an Irreversible Btk Inhibitor Compound

[0231] Where the subject is suffering from or at risk of suffering from an autoimmune disease, an inflammatory disease, or an allergy disease, an irreversible Btk inhibitor compound can be used in with one or more of the following therapeutic agents in any combination: immunosuppressants (e.g., tacrolimus, cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, or FTY720), glucocorticoids (e.g., prednisone, cortisone acetate, prednisolone, methylprednisolone, dexmethylsone, betamethasone, triamcinolone, beclomethasone, fludrocortisone acetate, deoxy corticosterone acetate, aldosterone), non-steroidal anti-inflammatory drugs (e.g., salicylates, arylalkanoic acids, 2-arylpropionic acids, N-aryl thranilic acids, oxicones, coxibis, or sulphonanilides), Cox-2-specific inhibitors (e.g., valdecoxib, celecoxib, or rofecoxib), leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquine, minocycline, TNF-α binding proteins (e.g., infliximab, etanercept, or adalimumab), abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, allergy vaccines, antihistamines, antilukenkotrienes, beta-agonists, theophylline, or anticholinergics.

[0232] Where the subject is suffering from or at risk of suffering from a B-cell proliferative disorder (e.g., plasma cell myeloma), the subject can be treated with an irre-
versible Btk inhibitor compound in any combination with one or more other anti-cancer agents. In some embodiments, one or more of the anti-cancer agents are proapoptotic agents. Examples of anti-cancer agents include, but are not limited to, any of the following: gossypol, genasense, polyphenol E, Chloroformin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, 17-N-allylamino-17- Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD188352. Taxol™, also referred to as “paclitaxel”, which is a well-known anti-cancer drug which acts by enhancing and stabilizing microtubule formation, and analogs of Taxol™, such as Taxotere™. Compounds that have the basic taxane skeleton as a common structure feature, have also been shown to have the ability to arrest cells in the G2-M phases due to stabilized microtubules and may be useful for treating cancer in combination with the compounds described herein.

Further examples of anti-cancer agents for use in combination with an irreversible Btk inhibitor compound include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; and antibodies (e.g., rituxan).

Other anti-cancer agents that can be employed in combination with an irreversible Btk inhibitor compound include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin, aclacinomycin; acodazole hydrochloride; acronine; adozene; aldesleukin; altretamine; amanitin; antitoxin; anturidine; amsacrine; anastrozole; antracyclines; asparaginase; asperlicin; azacitidine; azetepa; azotomycin; batimastat; benzo- dexamethasone; bisantrene hydrochloride; bisnaphyridamine; bisnaphyridamine; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; capecitabine; cafestol; cardenolide; carbetimor; carboplatin; carboplatin; carmustine; carucin hydrochloride; carzelesin; cedegolin; chlorambucil; cirolemycin; cladribine; cisplatin; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexoromaplatin; dezanoguanine; desazaguanine; dihydroxyurea; diziquone; doxorubicin; doxorubicin hydrochloride; drolonifene; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; efomithine hydrochloride; elsamitracin; enoloplatin; enzoptamide; epipodophyllotoxin; epirubicin hydrochloride; eruboldazole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; fluorouracil; fluoxymesterone; fosfamide; fosinopterin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ifosfamide; interleukin II (including recombinant interleukin II, or rIL-2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon beta-1a; interferon gamma-1 b; irinotecan hydrochloride; lanreotide acetate; letrozole; leucovorin; leuprolide acetate; lirozole hydrochloride; lometrexol sodium; lonidamine; lossaxartrine hydrochloride; masoprostol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; mitomycin; mitoxantrone; mitotane; mitozanolactone; mitoxantrone hydrochloride; mycophenolic acid; nocardazole; nogalamycin; ormaplatin; oxisuran; pegaspargase; pelomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plecanicin; plomestane; potefirmer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puramycin; purinomycin hydrochloride; pyrazofurin; riboprine; rogtidamine; safinol; safingol hydrochloride; semustine; sintrazene; sporoside sodium; sparsomycin; spirogermanium hydrochloride; spironomycin; spiroplatin; streptozocin; sulofenur; talosynomycin; tegocalan sodium; tegafur; teloxantrone hydrochloride; teniposide; temoporfin; teniposide; testolactone; thiamicrine; thioguanine; thiopeta; tiazofurin; tirapazamine; toremifene citrate; tretonoin; tribricbine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulose hydrochloride; uracil mustard; uridene; vaporetoine; vertoprin; vinblastine sulfate; vincristine sulfate; vin- desine; vinbesine sulfate; vindeplatin; vinflucinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zinostatin; zorubicin hydrochloride.
nists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; fludarabine; fluorodeoxyuridine hydrochloride; forfenimex; formentane; fostriecin; fotemustine; gadolinium tetraxphil; gallium nitrate; galactosamine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronate acid; idarubicin; idoxifene; idramantone; ilomosine; ilomastat; imidazoacridones; imiquimod; immunomimetics; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iboguanine; iododoxorubicin; ipomeanol; irit; iroplat; iroslgadine; isobezagole; isohomalciondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N-tricarate; lanreotide; leminycin; lenogastatin; lenitam sulfate; leptomostatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen/progestrone; leuprelirin; levamisole; liarozole; linear polynucleotide analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissocinamid A; lobalatin; lombricine; lometrexol; lonidamine; losoxantrene; lovastatin; losoxzoridine; lurtocetam; lutetium pharyn; lysophylline; lytic peptides; maitainsine; mammostatin A; marimastat; masoprolol; maspin; matrylsin inhibitors; matrix metalloprotease inhibitors; meningioma; merbarone; merelatin; methioninase; metoclopromide; MIF inhibitor; mifepristone; miltefosine; mimimostim; mismatched double stranded RNA; mitoguanine; mitolecost; mitomycin analogues; mitofamide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofetorene; molgramostim; monoclonal antibody; human chorionic gonadotrophin; monophosphoryl lipid A+mycobacterium cell wall; mopsi- damol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticaner agent; mycaperoxin B; mycobacterial cell wall extract; myriaporone; N-acetyldinaleine; N-substituted benzamides; nafarelin; nagrest; naloxone+pentazocine; napavin; naph- terpin; nartogastatin; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitrooxide antioxidant; nitronally; O6-benzylguanine; octreotide; oriconine; oligonucleotides; onapristone; ondosantron; ondosantron; oracin; oral cytokine inducer; ormaplatin; ostarone; oxaplatin; oxanomycin; palauamine; palmitoylprinazoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazazziliane; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perfubron; perfosfamide; periflery alcohol; phenazineoxycin; phenylacetate; phosphatase inhibitors; picibanil; pilrocarpine hydrochloride; pirurubicin; piriractin; placentin A; placentin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinium-triamine complex; porfimer sodium; porfitromycin; prednisone; propyl bis-acaridine; prostaglandin J2; protease inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors; microgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurasin; pyrazolocaridine; pyridoxylated hemoglobin polyoxycetilfer conjugate; raf antagonists; raltitrexed; ramotason; ras famesil protein transference inhibitors; ras inhibitors; ras-GAP inhibitor; retelipetine demethylated; rhenium Re 186 etdonenate; rhizoxin; ribosome; R11 retinamide; rogleitamide; rohitukine; romurtide; roquinimex; rubiginone B1; riboxygenol; safinogol; saintopin; SarCNU; sarcophtyol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonerin; sparafosic acid; spicamycin D; spironostine; splenopetin; spongistatin 1; squamlumine; stem cell inhibitor; stem-cell division inhibitors; stiptiamide; stromelysin inhibitors; sulfinosine; superactive vascularjntestinal peptide antagonist; suradista; suramin; swainsine; synthetic glycosaminoglycans; tallimustine; tamoxifen methylide; tauromustine; tazarotene; tecolagan sodium; tegafur; tellurapyrylum; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaxite; tetraxamines; thaliblastine; thioacoricel; throbopocetin; throbopoietsin mimetic; thymalin; thymopoeitin receptor agonist; thymotrin; thyroid stimulating hormone; tin ethyl etopurpurine; tirapazamine; tianacence biichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretoin; triacetlyuridine; tricibrine; trimetrexate; triptorelin; tiroseptrin; turosteride; tyrosine kinase inhibitors; tyrophostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vaperoid; varilin B, vector system, erythrocyte gene therapy; velresol; veramine; verlins; vorpersper; vinoroloxide; vinblastine; vitaxin; vorozole; zanoterone; zemiplatin; zilascor; and zinostatin stimulam.
pionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracyclinedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).

[0240] Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an irreversible Btk inhibitor compound include without limitation the following marketed drugs and development: Erlotinib (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isothionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABI-751 (Abbott, also known as E-7010), Altordithrin (such as Altordithrin A and Altordithrin C), Spongistatin (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Camadotin hydrochloride (also known as LU-103793 and NSC-D-669356), Epothilone (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxygenophosphate A or dP40A), Epothilone D (also referred to as KOS-862, dP40B, and desoxygenophosphate B), Epothilone E, Epothilone F, Epothilone N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminooxepophosphate B (also known as BMS-310705), 21-hydroxyepothilone D (also known as Desoxygenophosphate F and dP40F), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Sobradiotin (also known as TZJ-1027), LS-455-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Dui ichi), FR-182877 (Fujisawa, also known as WS-98853), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitiveluvamide, Tubulysin A, Canadensin, Cen twolein (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TL-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncodcin I (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolidide B, Lualimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Ncasepine, D-24851 (Asta Medica), A-105972 (Abbott), Heminsterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-191), TMPN (Arizona State University), Vanadocene acetylactone, T-138026 (Tularik), Monastrol, Iinanocine (also known as NSC-698666), 3-1AAAB (Cytoskeleton/Mt. Sinai School of Medicine, A-204197 (Abbott), T-607 (Tularik, also known as T-906007), RPR-115781 (Aventis), Eleutherobin (such as Desmethylleletherobin, Desaetylleletherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaesoside, Caribaesodin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Dizostatin, (--)Phenylationstibilin (also known as NSC-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resveratatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SBR-250411 (Sunofi).

[0241] Where the subject is suffering from or at risk of suffering from a thromboembolic disorder (e.g., stroke), the subject can be treated with an irreversible Btk inhibitor compound in any combination with one or more other anti-thromboembolic agents. Examples of anti-thromboembolic agents include, but are not limited any of the following: thrombolytic agents (e.g., alteplase anistreplase, streptokinase, urokinase, or tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran (e.g., dabigatran etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban, DX-9065a, atamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel, LY640315), ximelagatran, or BIBR 1048.

**EXAMPLES**

[0242] The following examples describe in detail the synthesis of ibritinib produgs of Formula (I), properties of ibritinib produgs of Formula (I), and uses of ibritinib produgs of Formula (I). It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the disclosure.

[0243] All reagents and solvents that can be purchased from commercial suppliers may be used without further purification or manipulation. Non-commercially available reagents may be synthesized from commercially available starting materials, and by adapting methods well known in the art.

[0244] Analytical LC/MS was performed on an Agilent 1100 equipped with AB Sciex API 2000 or a Waters 2790 equipped with a Waters Micromass QZ mass spectrometer and a Phenomenex Luna C-18 analytical column. Preparative HPLC purification was performed on an Agilent 1100. Both analytical and preparative HPLC used acetonitrile/water gradients containing 0.05% formic acid. Normal-phase silica gel purification was performed on a ISCO CombiFlash Companion purification system using either a mixture of methanol and dichloromethane or ethyl acetate and hexanes. Chemical names were generated with Accelrys Draw 4.1 SP1, version MDL.Drew.Editor 4.1.100.70 (Accelrys, Inc., San Diego, Calif.).
Example 1

[3-(4-Phenoxyphenyl)-1-[(3R)-1-prop-2-enoyl-3-piperidyl]pyrazolo[3,4-d]pyrimidin-4-yl]carbamoyloxymethyl acetate (1)

[0245]

A mixture of ibrutinib (15 mg, 1.0 eq), (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl acetate (1.5 eq), and NaHCO₃ (3.0 eq) in 1:1 water and acetonitrile (0.5 mL) was stirred at 20°C overnight. The reaction was then purified by reverse-phase (C-18) liquid chromatography using water and acetonitrile as eluents to yield compound (1). MS (ESI): m/z 557.2 (M+H)+.

Example 2

[3-(4-Phenoxyphenyl)-1-[(3R)-1-prop-2-enoyl-3-piperidyl]pyrazolo[3,4-d]pyrimidin-4-yl]carbamoyloxymethyl 2-methylpropanoate (2)

[0248]

Compound (2) was prepared according to the method described in Example 1 and substituting (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl acetate with (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl 2-methylpropanoate. MS (ESI): m/z 585.2 (M+H)+.

Example 3

[3-(4-Phenoxyphenyl)-1-[(3R)-1-prop-2-enoyl-3-piperidyl]pyrazolo[3,4-d]pyrimidin-4-yl]carbamoyloxymethyl cyclohexanecarboxylate (3)

[0250]

Compound (3) was prepared according to the method described in Example 1 and substituting (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl acetate with (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl cyclohexanecarboxylate. MS (ESI): m/z 625.3 (M+H)+.

Example 4

[3-(4-Phenoxyphenyl)-1-[(3R)-1-prop-2-enoyl-3-piperidyl]pyrazolo[3,4-d]pyrimidin-4-yl]carbamoyloxymethyl benzoate (4)

[0252]
Compound (4) was prepared according to the method described in Example 1 and substituting (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl acetate with (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl benzate. MS (ESI): m/z 619.2 (M+H)+.

Example 5

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl N-[3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoyl-3-piperidyl]pyrazolo[3,4-d]pyrimidin-4-yl]carbamate (5)

Compound (5) was prepared according to the method described in Example 1 and substituting (2,5-dioxopyrrolidin-1-yl)oxycarbonyloxymethyl acetate with (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl carbonochloridate. MS (ESI): m/z 597.2 (M+H)+.

1. A method for treating a non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, or chronic lymphocytic leukemia with 17p deletion comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): (I)

A is N;
each R'^1, R'^2, R'^3, and R'^4 is H;
R'^5 is phenoxy;
R^2 is H;
R^3 is the following structure:

and

Z is selected from the following structures:

wherein each R'^1, R'^2, and R'^3 is independently selected from H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, substituted or unsubstituted lower heterocycloalkyl, and substituted or unsubstituted lower aryl, wherein each substituent is independently selected from —F, —Cl, —CF₃, —CN, —NO₂, —OH, —OCH₃, and —NH₂.

2. The method of claim 1, wherein the non-Hodgkin lymphoma is selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma.

3. (canceled)

4. (canceled)

5. (canceled)

6. The method of claim 1, wherein the compound is administered orally.

8. The method of claim 7, wherein the non-Hodgkin lymphoma is selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma.

9. (canceled)
10. (canceled)
11. (canceled)
12. The method of claim 7, wherein the compound is administered orally.


14. The method of claim 13, wherein the non-Hodgkin lymphoma is selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma.

15. (canceled)
16. (canceled)
17. (canceled)
18. The method of claim 13, wherein the compound is administered orally.

* * * * *